Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
Provided By GlobeNewswire
Last update: Aug 6, 2024
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease -
